In Phase C, individuals will obtain ABBV-744 and oral navitoclax. In Segment D, participants will receive ABBV-744 and ruxolitinib. Participants will receive treatment right up until disorder progression or maybe the contributors are unable to tolerate the study drugs. Celastrol was discovered as being a Myb inhibitor that suppressed C/EBPβ https://abbiep887cny0.ktwiki.com/user